MergerMay 14, 2026, 03:16 PM
Telomir Pharmaceuticals Completes Merger with TELI Pharma
AI Summary
Telomir Pharmaceuticals completed its merger with TELI Pharmaceuticals, Inc. on April 22, 2026, issuing 34,389,710 restricted shares to former TELI stockholders. The company also announced FDA IND clearance for Telomir-Zn to initiate a clinical trial for triple-negative breast cancer. For the three months ended March 31, 2026, Telomir reported a reduced net loss of $0.99 million, down from $2.18 million year-over-year, and a net loss per share of $0.03. However, the company faces substantial doubt about its ability to continue as a going concern due to insufficient cash to support operations for the next 12 months.
Key Highlights
- Completed merger with TELI Pharmaceuticals on April 22, 2026, issuing 34,389,710 restricted shares.
- Received FDA IND clearance for Telomir-Zn to initiate a clinical trial for triple-negative breast cancer.
- Reported a net loss of $990,947 for Q1 2026, an improvement from $2,179,828 in Q1 2025.
- Basic and diluted net loss per share was $0.03 for Q1 2026, down from $0.07 in Q1 2025.
- Cash balance decreased to $5,560,511 as of March 31, 2026, from $7,286,670 at December 31, 2025.
- Net cash used in operating activities increased to $1,773,510 in Q1 2026 from $863,132 in Q1 2025.
- Company faces substantial doubt about its ability to continue as a going concern for the next 12 months.
Price Impact
More from TELO